UPDATE 1-Ionis Pharma's genetic disease drug succeeds in late-stage study

[admin]

Ionis Pharmaceuticals said on Monday its drug for the treatment of a rare genetic disease met the main goal of a late-stage trial. The drug, donidalorsen, was more successful than placebo in reducing the rate of attacks in patients with hereditary angioedema. Hereditary angioedema is a rare and life-threatening genetic disease that causes unpredictable and frequent severe swelling of the skin, gastrointestinal tract, upper respiratory system, face and throat.